このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Antibe Therapeutics 将来の成長

Future 基準チェック /06

Antibe Therapeuticsは、27.2%と67%でそれぞれ年率27.2%で利益と収益が成長すると予測される一方、EPSはgrowで27.2%年率。

主要情報

27.2%

収益成長率

27.2%

EPS成長率

Pharmaceuticals 収益成長	72.0%
収益成長率	67.0%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	26 Apr 2024

今後の成長に関する最新情報

Recent updates

Need To Know: The Consensus Just Cut Its Antibe Therapeutics Inc. (CVE:ATE) Estimates For 2021

Jul 29

業績と収益の成長予測

TSX:ATE - アナリストの将来予測と過去の財務データ ( )CAD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
3/31/2027	N/A	-25	N/A	N/A	1
3/31/2026	N/A	-24	N/A	N/A	1
3/31/2025	N/A	-15	N/A	N/A	1
3/31/2024	N/A	-20	N/A	N/A	2
12/31/2023	N/A	-18	-18	-18	N/A
9/30/2023	N/A	-18	-18	-18	N/A
6/30/2023	N/A	-19	-16	-16	N/A
3/31/2023	N/A	-19	-16	-16	N/A
12/31/2022	N/A	-21	-17	-17	N/A
9/30/2022	N/A	-22	-15	-15	N/A
6/30/2022	N/A	-24	-17	-17	N/A
3/31/2022	N/A	-25	-17	-17	N/A
12/31/2021	N/A	-26	6	6	N/A
9/30/2021	N/A	-26	1	1	N/A
6/30/2021	-1	-25	-1	-1	N/A
3/31/2021	N/A	-24	0	0	N/A
12/31/2020	2	-25	-22	-22	N/A
9/30/2020	5	-23	-18	-18	N/A
6/30/2020	8	-21	-13	-13	N/A
3/31/2020	10	-19	-11	-11	N/A
12/31/2019	10	-17	-9	-9	N/A
9/30/2019	10	-16	-8	-8	N/A
6/30/2019	10	-13	-7	-7	N/A
3/31/2019	10	-13	-7	-7	N/A
12/31/2018	9	-11	-8	-8	N/A
9/30/2018	9	-9	-8	-8	N/A
6/30/2018	9	-8	-7	-7	N/A
3/31/2018	9	-7	-7	-6	N/A
12/31/2017	9	-7	-6	-6	N/A
9/30/2017	8	-7	N/A	-5	N/A
6/30/2017	9	-6	N/A	-4	N/A
3/31/2017	9	-6	N/A	-3	N/A
12/31/2016	9	-5	N/A	-3	N/A
9/30/2016	9	-4	N/A	-3	N/A
6/30/2016	7	-4	N/A	-3	N/A
3/31/2016	4	-3	N/A	-3	N/A
12/31/2015	2	-3	N/A	-2	N/A
9/30/2015	N/A	-3	N/A	-2	N/A
6/30/2015	0	-3	N/A	-3	N/A
3/31/2015	N/A	-4	N/A	-4	N/A
12/31/2014	N/A	-5	N/A	-5	N/A
9/30/2014	N/A	-5	N/A	-4	N/A
6/30/2014	N/A	-4	N/A	-4	N/A
3/31/2014	N/A	-3	N/A	-3	N/A
12/31/2013	N/A	-2	N/A	-2	N/A
9/30/2013	N/A	-1	N/A	-2	N/A

アナリストによる今後の成長予測

収入対貯蓄率: ATE今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ATE今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: ATE今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ATE来年は収益がないと予測されています。

高い収益成長: ATE来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ATEの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Antibe Therapeutics 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Price target decreased by 14% to CA$1.50

No longer forecast to breakeven

Forecast to breakeven in 2026

Price target increased by 12% to CA$2.35

Price target increased to CA$2.35

Price target decreased to CA$2.09

Recent updates

Antibe Therapeutics Inc. Announces Board Resignations

Antibe Therapeutics Inc. Announces Board Resignations

New major risk - Market cap size

Nuance Pharma Limited Commences Legal Action Against Antibe Therapeutics Inc. in the Ontario Superior Court Legal Action

Price target decreased by 14% to CA$1.50

New minor risk - Profitability

Is Antibe Therapeutics (TSE:ATE) In A Good Position To Invest In Growth?

Insufficient new directors

Antibe Therapeutics Inc. Reports PK Results of First Clinical Study of Otenaproxesul’s New Formulation

New minor risk - Share price stability

Antibe Completes First Clinical Study of Otenaproxesul’s New Formulation

Antibe Initiates First Clinical Study of Otenaproxesul’s New Formulation

Antibe Therapeutics Inc. Receives Approval to Initiate PK/PD Study of Otenaproxesul

New minor risk - Profitability

No longer forecast to breakeven

New minor risk - Profitability

Antibe Therapeutics Inc., Annual General Meeting, Sep 08, 2023

Forecast to breakeven in 2026

Price target increased by 12% to CA$2.35

We Think Antibe Therapeutics (TSE:ATE) Needs To Drive Business Growth Carefully

Antibe Therapeutics Inc. Announces Retirement of Dr. John L. Wallace from the Board of Directors

Price target increased to CA$2.35

Founder & Vice Chair recently sold CA$122k worth of stock

Price target decreased to CA$2.09

HANSAmed Limited completed the acquisition of Citagenix Inc from Antibe Therapeutics Inc. (TSX:ATE) for CAD 6.5 million.

Antibe Therapeutics Inc. Provides Development Update for Otenaproxesul

Price target decreased to CA$2.09

First quarter 2023 earnings released: CA$0.11 loss per share (vs CA$0.13 loss in 1Q 2022)

Founder & Vice Chair recently sold CA$88k worth of stock

Price target decreased to CA$2.93

Antibe Therapeutics Inc., Annual General Meeting, Sep 09, 2022

Antibe Therapeutics Appoints New Board Chair and Corporate Vice Chairs

HANSAmed Limited entered into an agreement to acquire Citagenix Inc. from Antibe Therapeutics Inc. (TSX:ATE) for CAD 6.5 million

Consensus revenue estimates increase by 112%

Price target decreased to CA$2.53

Consensus revenue estimates increase to CA$1.81m

Consensus forecasts updated

Second quarter 2022 earnings released: CA$0.16 loss per share (vs CA$0.21 loss in 2Q 2021)

President recently bought CA$100k worth of stock

Antibe Therapeutics (TSE:ATE) Is In A Strong Position To Grow Its Business

First quarter 2022 earnings released: CA$0.13 loss per share (vs CA$0.16 loss in 1Q 2021)

Consensus forecasts updated

Price target decreased to CA$10.20

No longer forecast to breakeven

No longer forecast to breakeven

Full year 2021 earnings released: CA$0.66 loss per share (vs CA$0.71 loss in FY 2020)

Price target decreased to CA$15.09

Independent Chair of the Board recently sold CA$400k worth of stock

Antibe Therapeutics Inc. has completed a Composite Units Offering in the amount of CAD 35.1 million.

Price target raised to CA$16.96

Third quarter 2021 earnings released: CA$0.15 loss per share (vs CA$0.15 loss in 3Q 2020)

Revenue and earnings beat expectations

Analysts update estimates

Antibe Therapeutics Inc.'s (TSE:ATE) Profit Outlook

Nuance Pharma Announces Strategic Licensing Deal with Antibe Therapeutics in China

New 90-day high: CA$5.76

Antibe Therapeutics Inc. Appoints Don Haut to Its Partnering Advisory Team

We're Keeping An Eye On Antibe Therapeutics' (TSE:ATE) Cash Burn Rate

Analysts update estimates

Analysts update estimates

Antibe Therapeutics Inc. Announces Board Appointments

Analysts update estimates

Second quarter 2021 earnings released: CA$0.021 loss per share

Revenue and earnings beat expectations

Antibe Therapeutics Inc.(TSXV:ATE) dropped from S&P/TSX Venture Composite Index

New 90-day low: CA$0.32

Price target lowered to CA$1.86

New 90-day low: CA$0.36

Analysts lower revenue estimates to CA$8.26m